Companies: 10,795·Total market cap: $144.5T
Seres Therapeutics, Inc.

Seres Therapeutics, Inc.

MCRBNASDAQHealthcare● Active
$6.28
$-0.35(-5.28%)
Market Cap$60815080
P/E Ratio
52W High$29.98
52W Low$6.01
Overview

Seres Therapeutics, Inc. (MCRB) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · MCRB · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-5.18mcrb eps ttm · mcrb earnings per shareEarnings history
PE Ratio (TTM)mcrb pe ratio ttm · mcrb price to earningsPE Ratio deep dive
Revenue (TTM)$1.1Mmcrb revenue ttm · mcrb annual revenueFull revenue history
Dividend YieldNo Dividenddoes mcrb pay dividends · mcrb dividend yieldDividend history
Shares Outstanding8.9Mmcrb shares outstanding · mcrb floatShares outstanding history
Next EarningsAug 5, 2026Est.mcrb earnings date · mcrb next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$789000.00
202320242025
seres therapeutics, inc. revenue · mcrb revenue 2025
FY 2025Net Income$5.7M▲ +103.89% YoY
202320242025
seres therapeutics, inc. net income · mcrb profit 2025
FY 2025EPS$0.64▲ +103.39% YoY
202320242025
mcrb eps · seres therapeutics, inc. earnings per share 2025
TTM:Revenue: $1.1MNet Income: -$46.9MEPS: $-5.18View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy18 analystsis mcrb a buy · mcrb analyst rating
Strong Buy
0
Buy
11
Hold
3
Sell
4
Strong Sell
0
12-Month Price Target
$1.25Low
$6.28Current
$1.25Avg Target80.10% downside
$1.25High
mcrb price target · mcrb 12 month forecast

Total: 18 · Buy rate: 61.1%

The MCRB analyst consensus is Buy, based on ratings from 18 Wall Street analysts over the past 3 months. The average 12-month price target is $1.25, representing -80.10% downside from the current price of $6.28.

Stock Performance

Full History
1D-5.28%
1W-12.66%
1M-18.44%
3M-31.22%
YTD-57.80%
1Y-22.94%
5Y-98.41%

About Seres Therapeutics, Inc.

CEORichard N. Kender
IPO DateJun 26, 2015
Employees103
CountryUS

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship thera…

what is seres therapeutics, inc. · mcrb stock overview · seres therapeutics, inc. company profile · who is seres therapeutics, inc. ceo · mcrb NASDAQ · seres therapeutics, inc. headquarters · seres therapeutics, inc. business segments

About Stock Overview & Key Data

Seres Therapeutics, Inc. (MCRB) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 26, 2015. As of the latest trading session, MCRB stock price is $6.28, with a market capitalization of $60.8M. The stock has returned -22.94% over the past 12 months and -57.80% year-to-date.

According to 18 Wall Street analysts, the consensus rating for Seres Therapeutics, Inc. stock is Buy, with an average 12-month price target of $1.25. In fiscal year 2025, Seres Therapeutics, Inc. reported revenue of $789000.00 and net income of $5.7M. For detailed data — including Seres Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Seres Therapeutics, Inc. (MCRB) stock price is $6.28. The stock is traded on NASDAQ under the ticker symbol MCRB. The 52-week range is $6.01 – $29.98.

MCRB stock priceMCRB quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice